These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23876458)

  • 41. Boceprevir.
    Prescrire Int; 2012 Apr; 21(126):89-92. PubMed ID: 22515132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C.
    Yang S; Xing H; Feng S; Ju W; Liu S; Wang X; Ou W; Cheng J; Pan CQ
    Arch Virol; 2018 Feb; 163(2):467-473. PubMed ID: 29143142
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.
    Klibanov OM; Vickery SB; Olin JL; Smith LS; Williams SH
    Pharmacotherapy; 2012 Feb; 32(2):173-90. PubMed ID: 22392426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
    Jacobson IM; Pawlotsky JM; Afdhal NH; Dusheiko GM; Forns X; Jensen DM; Poordad F; Schulz J
    J Viral Hepat; 2012 May; 19 Suppl 2():1-26. PubMed ID: 22404758
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.
    Chen KX; Njoroge FG
    Prog Med Chem; 2010; 49():1-36. PubMed ID: 20855037
    [No Abstract]   [Full Text] [Related]  

  • 47. [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].
    Kozielewicz D; Halota W; Dybowska D
    Przegl Epidemiol; 2012; 66(1):49-54. PubMed ID: 22708298
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
    Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
    Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel molecular mechanism to explain mutations of the HCV protease associated with resistance against covalently bound inhibitors.
    Nazario de Moraes L; Tommasini Grotto RM; Targino Valente G; de Carvalho Sampaio H; Magro AJ; Fogaça L; Wolf IR; Perahia D; Faria Silva G; Plana Simões R
    Virus Res; 2019 Dec; 274():197778. PubMed ID: 31618615
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection.
    Hazuda DJ; Burroughs M; Howe AY; Wahl J; Venkatraman S
    Ann N Y Acad Sci; 2013 Jul; 1291():69-76. PubMed ID: 23859802
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of HCV NS3 Protease Variants in HCV/HIV-Coinfected Patients by Ultra-Deep Sequence Analysis: Relationship with Hepatic Fibrosis.
    Abdel-Hameed EA; Rouster SD; Zhang X; Chen J; Medvedovic M; Goodman ZD; Sherman KE
    J Acquir Immune Defic Syndr; 2017 Mar; 74(3):353-358. PubMed ID: 27898525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
    Welsch C; Jesudian A; Zeuzem S; Jacobson I
    Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay.
    Curry S; Qiu P; Tong X
    J Virol Methods; 2008 Nov; 153(2):156-62. PubMed ID: 18755220
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV.
    Noble CF; Malta F; Lisboa-Neto G; Gomes-Gouvêa MS; Leite AGB; de Castro VFD; Santana RAF; Carrilho FJ; Mendes-Correa MC; Pinho JRR
    Arch Virol; 2017 Jan; 162(1):165-169. PubMed ID: 27704215
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
    Butt AA; Kanwal F
    Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Future of hepatitis C therapy: development of direct-acting antivirals.
    Dore GJ; Matthews GV; Rockstroh J
    Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anemia management in patients with chronic viral hepatitis C.
    Hynicka LM; Heil EL
    Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study.
    Dierynck I; Thys K; Ghys A; Sullivan JC; Kieffer TL; Aerssens J; Picchio G; De Meyer S
    J Infect Dis; 2014 Dec; 210(12):1871-80. PubMed ID: 24943725
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
    Sarrazin C
    J Hepatol; 2016 Feb; 64(2):486-504. PubMed ID: 26409317
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs.
    Raja R; Pareek A; Newar K; Dixit NM
    PLoS Pathog; 2019 Apr; 15(4):e1007701. PubMed ID: 30934020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.